401 related articles for article (PubMed ID: 23050510)
1. The FDA's assessment of two drugs for chronic weight management.
Colman E; Golden J; Roberts M; Egan A; Weaver J; Rosebraugh C
N Engl J Med; 2012 Oct; 367(17):1577-9. PubMed ID: 23050510
[No Abstract] [Full Text] [Related]
2. 2 new drugs for weight loss.
Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487
[No Abstract] [Full Text] [Related]
3. Two anti-obesity hopefuls and their safety.
Bello NT; Campbell SC
Expert Opin Drug Saf; 2012 Sep; 11(5):681-3. PubMed ID: 22788876
[No Abstract] [Full Text] [Related]
4. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
5. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Shyh G; Cheng-Lai A
Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
[TBL] [Abstract][Full Text] [Related]
6. Two new drugs approved for obesity.
Johnson AM
S D Med; 2012 Sep; 65(9):356-7. PubMed ID: 23066610
[No Abstract] [Full Text] [Related]
7. Nonincretin drugs in later-stage development.
Zimmerman MP; Mehr SR
Am J Manag Care; 2014 Jan; 20(1 Spec No.):E2. PubMed ID: 25618226
[No Abstract] [Full Text] [Related]
8. Drug management of obesity--efficacy versus safety.
Astrup A
N Engl J Med; 2010 Jul; 363(3):288-90. PubMed ID: 20647205
[No Abstract] [Full Text] [Related]
9. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
Rubio MA
Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595
[No Abstract] [Full Text] [Related]
10. Market watch: upcoming market catalysts in Q3 2010.
Hay M
Nat Rev Drug Discov; 2010 Jul; 9(7):507. PubMed ID: 20592737
[No Abstract] [Full Text] [Related]
11. Obesity Epidemic: Pharmaceutical Weight Loss.
Curry SA
R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654
[TBL] [Abstract][Full Text] [Related]
12. Diet drugs Belviq and Qsymia receive FDA approval: what dentists need to know.
Wynn RL
Gen Dent; 2013; 61(1):11-3. PubMed ID: 23302354
[No Abstract] [Full Text] [Related]
13. The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen.
Azebu LM
Food Drug Law J; 2014; 69(1):87-111, ii-iii. PubMed ID: 24772687
[TBL] [Abstract][Full Text] [Related]
14. Unambiguous identification of obesity trials.
Zarin DA; Tse T
N Engl J Med; 2013 Feb; 368(6):580-1. PubMed ID: 23388022
[No Abstract] [Full Text] [Related]
15. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
Bays HE; Gadde KM
Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915
[TBL] [Abstract][Full Text] [Related]
16. Combination phentermine/topiramate for obesity treatment in primary care: a review.
Xiong GL; Gadde KM
Postgrad Med; 2014 Mar; 126(2):110-6. PubMed ID: 24685974
[TBL] [Abstract][Full Text] [Related]
17. Panel meeting prompts excitement for antiobesity drug.
Mullard A
Lancet; 2012 Mar; 379(9819):882. PubMed ID: 22413140
[No Abstract] [Full Text] [Related]
18. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
Woloshin S; Schwartz LM
JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
[TBL] [Abstract][Full Text] [Related]
19. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
20. Lemons for obesity.
Lauer MS
Ann Intern Med; 2012 Jul; 157(2):139-40. PubMed ID: 22801677
[No Abstract] [Full Text] [Related]
[Next] [New Search]